Peptide Record

Semaglutide · full corpus

Explore

Every evidence record, mention, review and regulatory filing collected for Semaglutide, in one list. Each row links to the original. Nothing here is summarised for you — this is the corpus, source tag by source tag.

2,935 records · ordered by source hierarchy — human trials first, vendor material last

Corpus records for Semaglutide
SourceKindRecordAttributionDetailDate
HUMAN-TRIALevidenceMuscle atrophy associated with glucagon-like Peptide-1 receptor agonists: A population-based observational study.Semaglutidehuman-observational2026-05-01
HUMAN-TRIALevidenceSemaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial.Semaglutidehuman-rct2026-05-01
HUMAN-TRIALevidenceBMI response to dapagliflozin with or without semaglutide across obesity classes: a real-world observational study conducted in Saudi Arabia.SemaglutideWeight & fat loss · human-observational2026-05-01
HUMAN-TRIALevidenceToward Precision Obesity Pharmacotherapy: Using the Eating Behavior Phenotype Scale (EFCA) in Real-World Clinical Practice.SemaglutideWeight & fat loss · human-observational2026-04-30
HUMAN-TRIALevidenceComparison of Semaglutide and Lifestyle Counselling for Weight Loss Using Multi-Site Electronic Health Records.SemaglutideWeight & fat loss · human-observational2026-04-01
HUMAN-TRIALevidenceAssociation between GLP-1 receptor agonist use and worsening mental illness in people with depression and anxiety in Sweden: a national cohort study.SemaglutideMood & anxiety · human-observational · n = 954902026-04-01
HUMAN-TRIALevidenceReal-world effectiveness of oral semaglutide on body weight, composition, and metabolic parameters in patients with obesity without diabetes.semaglutidaWeight & fat loss · human-observational · n = 702026-04-01
HUMAN-TRIALevidenceSimulated shared and supported decision making for amyloid immunotherapy in Alzheimer's disease: A bicentric study.SemaglutideCognition & memory · human-observational · n = 252026-04-01
HUMAN-TRIALevidenceInpatient safety, effectiveness of SGLT2 inhibitors and GLP-1 RAs in type 2 diabetes: ENDOCARE, a pragmatic prospective cohort study.SemaglutideGlycemic control · human-observational2026-03-30
HUMAN-TRIALevidenceBispecific GLP-1/GLP-2 agonism in advanced type 2 diabetes: preclinical characterization and a randomized, double-blind, placebo-controlled phase I trial.SemaglutideGlycemic control · human-rct2026-03-24
HUMAN-TRIALevidenceEfficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial.SemaglutideGlycemic control · human-rct2026-03-21
HUMAN-TRIALevidenceImpact of oral semaglutide on quality of life and metabolic parameters in patients with type 2 diabetes mellitus: A multicenter observational study.semaglutidaGlycemic control · human-observational · n = 432026-03-01
HUMAN-TRIALevidenceBimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial.SemaglutideWeight & fat loss · human-rct2026-03-01
HUMAN-TRIALevidencePreliminary Real-World Experience with Semaglutide in Obese Patients with Type 2 Diabetes on Chronic Hemodialysis: A Multicenter Pilot Study.Semaglutidehuman-observational2026-02-16
HUMAN-TRIALevidencePatients after acute myocardial infarction: potential of semaglutide in prognosis for reducing events and mortality.semaglutidaGlycemic control · human-observational2026-02-01
HUMAN-TRIALevidenceFecal microbiome predicts treatment response after the initiation of semaglutide or empagliflozin uptake.OzempicGlycemic control · human-observational2026-01-24
HUMAN-TRIALevidenceReal-world glycemic control, exploratory cardiorenal indicators, and safety of polyethylene glycol loxenatide versus semaglutide in type 2 diabetes patients: a Chinese two-center retrospective cohort study.SemaglutideGlycemic control · human-observational2026-01-01
HUMAN-TRIALevidenceDrug-induced gastric motility disorders: A disproportionality analysis from the FAERS and CVARD databases.SemaglutideGut barrier & GI healing · human-observational2026-01-01
HUMAN-TRIALevidenceImpact of semaglutide 2.4 mg on healthcare resource utilization and medical costs in patients with atherosclerotic cardiovascular disease in the United States (SHINE-ASCVD).WegovyWeight & fat loss · human-observational2025-12-01
HUMAN-TRIALevidenceReal-World Weight Loss Observed With Semaglutide and Tirzepatide in Patients with Overweight or Obesity and Without Type 2 Diabetes (SHAPE).WegovyWeight & fat loss · human-observational · n = 99162025-11-01
HUMAN-TRIALevidenceSemaglutide 2.4 mg Clinical Outcomes in Patients with Obesity or Overweight: A Real-World Retrospective Comparative Cohort Study.WegovyWeight & fat loss · human-observational2025-10-01
HUMAN-TRIALevidenceBlinded by the drug? A vigilyze signal linking semaglutide to NAION.OzempicGlycemic control · human-observational2025-09-30
HUMAN-TRIALevidenceEfficacy of once-weekly semaglutide in patients with heart failure with preserved ejection fraction, obesity and type 2 diabetes.semaglutidahuman-observational2025-09-01
HUMAN-TRIALevidenceHarnessing Facebook to Investigate Real-World Mentions of Adverse Events of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications: Observational Study of Facebook Posts From 2022 to 2024.OzempicGlycemic control · human-observational2025-07-24
HUMAN-TRIALevidenceTikTok's take on adverse effects for glucagon-like peptide-1 and gastric inhibitory polypeptide receptor agonists.Ozempichuman-observational2025-07-01
HUMAN-TRIALevidencePrescriptions for Obesity Medications Among Adolescents Aged 12-17 Years with Obesity - United States, 2018-2023.WegovyWeight & fat loss · human-observational2025-06-05
HUMAN-TRIALevidenceObesity and Metabolic Disease Impair the Anabolic Response to Protein Supplementation and Resistance Exercise: A Retrospective Analysis of a Randomized Clinical Trial with Implications for Aging, Sarcopenic Obesity, and Weight Management.OzempicMuscle growth & preservation · human-rct2024-12-23
HUMAN-TRIALevidence[The GLP-1 analogue battle: effects of semaglutide 0,5 mg/weekly versus liraglutide 3 mg/daily on anthropometric parameters after 3 months in a real world-scenario].semaglutidaWeight & fat loss · human-observational · n = 1792024-12-19
HUMAN-TRIALevidenceEfficacy and safety of semaglutide: real-world tertiary care experience from Saudi Arabia.OzempicGlycemic control · human-observational2024-11-01
HUMAN-TRIALevidenceReal-World Use of Semaglutide for Weight Management: Patient Characteristics and Dose Titration-A Danish Cohort Study.WegovyGlycemic control · human-observational · n = 1107482024-10-01
HUMAN-TRIALevidence[Oral semaglutide, first oral GLP-1 receptor agonist (Rybelsus(R))].RybelsusGlycemic control · human-rct2021-12-01
HUMAN-TRIALevidenceLong Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic TrialSemaglutideGlycemic control · human-rct · n = 1278—
HUMAN-TRIALevidenceA Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or TogetherOzempicGlycemic control · human-rct · n = 30—
HUMAN-TRIALevidenceRepurposing Semaglutide for the Treatment of Cocaine Use DisorderSemaglutidehuman-rct · n = 75—
HUMAN-TRIALevidenceGLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort StudySemaglutideWeight & fat loss · human-observational · n = 2310—
HUMAN-TRIALevidenceA Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical PracticeSemaglutideGlycemic control · human-observational · n = 194—
HUMAN-TRIALevidenceA Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical PracticeSemaglutideGlycemic control · human-observational · n = 465—
HUMAN-TRIALevidenceRetrospective Analysis for Patients With Metabolic SyndromeSemaglutidehuman-observational · n = 400—
HUMAN-TRIALevidencePost-Marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ozempic®SemaglutideGlycemic control · human-observational · n = 3217—
HUMAN-TRIALevidenceHolding vs. Continuing Incretin-based Therapies Before Upper EndoscopySemaglutidehuman-rct · n = 69—
HUMAN-TRIALevidenceEffects of Dapagliflozin, Semaglutide, and Their Combination in Heart Failure Patients With Prosthetic Heart ValvesSemaglutideLipid & cardiovascular markers · human-rct · n = 160—
HUMAN-TRIALevidenceEmulating the PIONEER6 Diabetes Trial Using Healthcare ClaimsSemaglutideGlycemic control · human-observational · n = 26126—
HUMAN-TRIALevidenceA Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Lisinopril and Warfarin in Healthy SubjectsSemaglutideGlycemic control · human-observational · n = 52—
HUMAN-TRIALevidenceEfficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 DiabetesSemaglutideGlycemic control · human-rct · n = 788—
HUMAN-TRIALevidenceImpact of Semaglutide on Tobacco Use and Related Health BehaviorsOzempichuman-rct · n = 40—
HUMAN-TRIALevidenceGLP-1 Receptor Agonist in Primary Intracerebral Hemorrhage: A Phase 2 Randomized TrialSemaglutidehuman-rct · n = 200—
HUMAN-TRIALevidenceAnti-obesity Pharmacotherapy and InflammationWegovyWeight & fat loss · human-observational · n = 30—
HUMAN-TRIALevidenceAlleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous SemaglutideSemaglutideGlycemic control · human-rct · n = 26—
HUMAN-TRIALevidenceEfficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 DiabetesSemaglutideGlycemic control · human-rct · n = 1231—
HUMAN-TRIALevidenceSemaglutide in CFRDSemaglutideGlycemic control · n = 8—